Obesity

Oprah Winfrey Tackles Weight Loss Drug Stigma In Prime-Time Special Amid Wegovy-Ozempic Frenzy: 'For 25 Years, Making Fun Of My Weight Was National Sport'
US Health Agency Reviews Novo Nordisk's Wegovy For Potential Use In Treating Heart Disease Patients With Obesity
Ozempic Maker Novo Nordisk To Introduce Obesity Drug Wegovy In Japan, Acknowledging Country's Rising Weight Issue
US Health Agency Reviews Novo Nordisk's Wegovy For Potential Use In Treating Heart Disease Patients With Obesity
Ozempic Maker Novo Nordisk To Introduce Obesity Drug Wegovy In Japan, Acknowledging Country's Rising Weight Issue
WeightWatchers Stock Falls After Q4 Results, Oprah Winfrey Exits
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market

Obesity Recent News

This Original Psychedelic-Based Obesity Treatment Set To First-In-Human Trials
Psychedelics biopharma company Clearmind Medicine Inc. (NASDAQ: CMND) and clinical-stage firm SciSparc Ltd.
Banning KFC, McDonald's Near Schools — How Western Australia Plans To Tackle Obesity
Elon Musk Says His Neuralink Chip Could Treat Paralysis, Stroke And Brain Injury
Tesla Inc (NASDAQ: TSLA) CEO Elon Musk's startup Neuralink brain chip could help treat morbid obesity; that's what Musk believes. Echoing Musk's statement, scientists say it's not an impossibility. 
Altimmune's Mid-Stage Pemvidutide Study Cleared By FDA For Obesity
The FDA has cleared Altimmune Inc's (NASDAQ:
Novo Nordisk Shares Slump As Wegovy Hits US Supply Issues; Deutsche Bank Downgrades
Novo Nordisk A/S (NYSE: NVO) said that a contract manufacturer filling syringes for pens to inject Wegovy (semaglutide) had 
European Authorities Recommend Approval Of Wegovy For Obesity
H.C. Wainwright Sees Buying Opportunity In This Biotech Stock Sell Off
H.C. Wainwright said that Altimmune Inc (NASDAQ: ALT) reported "positive" Phase 1 trial pemvidutide data, formerly known as ALT-801, in obese patients. 
See Why Altimmune Stock Plunged After Obesity Trial Data
Altimmune Inc (NASDAQ: ALT) has announced results from a 12-week, Phase 1 trial of pemvidutide (ALT-801), an investigational glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist.
Rhythm Pharma's ImciVree Gets European Approval For Obesity, Control of Hunger Associated With Genetic Mutations
FDA-Approved Weight Loss Drug Plenity's Parent Announces SPAC Deal: What Investors Should Know
A SPAC deal announced Monday could help accelerate the manufacturing of a promising weight loss drug targeting over 150 million people. 
9 Meters Biopharma Acquires Anti-GIP Monoclonal Antibody For Obesity-Related Disorders
Regeneron Discovers GPR75 Gene Mutations Can Protect Against Obesity, Begins Search For New Drugs
Novo Nordisk's Semaglutide Gets FDA Approval to Tackle Obesity
Why Technology Could Be The Answer For The Global Obesity Epidemic
Since 1975, global obesity levels have tripled. The most recent figures from the World Health Organization (WHO) found that over 1.9 billion adults were overweight and over 650 million were obese. These figures continue to rise despite attempts by governments and organizations to reverse the trends.
No­vo Nordisk To Start Phase 3 Obe­si­ty Tri­al With Oral Semaglu­tide
NLS Pharmaceutics Stock Surges On Obesity Drug Licensing Pact With Novartis Pharma
NLS Pharmaceutics AG (NASDAQ: NLSP) stock has more than doubled in reaction to a 
Researchers Find Endocannabinoids In Gut Might Regulate Obesity
Supersize Me Again: McDonald's Wants You To Curl Up With A Big Mac In New Sweats, Jammies Lines
EnteroMedics Plunged 28% Plunge, Explained
Exclusive: Orexigen Therapeutics Execs Talk Contrave And The Stock's Roller-Coaster Ride
Thromboembolic Risks Linger For Zafgen's Beloranib, Says SunTrust
Why Zafgen Is Trading Higher By 40%
Can Marijuana Help With Diabetes? Research Is Conflicting